论文部分内容阅读
目的探讨糖链抗原(carbohydrate antigen,CA)19-9在胰腺癌早期诊断中价值。方法胰腺癌患者35例(观察组)与同期40名健康体检者(对照组),应用化学发光免疫分析法检测2组血清CA19-9水平,比较2组CA19-9水平及阳性率,并分析不同分期胰腺癌患者血清CA19-9水平变化情况。结果观察组血清CA19-9水平、CA19-9阳性率高于对照组(P<0.05);随胰腺癌分期增加,患者CA19-9水平增高,但不同分期患者CA19-9水平比较差异无统计学意义(P>0.05)。结论 CA19-9可作为诊断早期胰腺癌及判断病情分期的指标。
Objective To investigate the value of carbohydrate antigen (CA) 19-9 in the early diagnosis of pancreatic cancer. Methods 35 patients with pancreatic cancer (observation group) and 40 healthy subjects (control group) were enrolled in this study. Serum CA19-9 level was measured by chemiluminescence immunoassay. The level of CA19-9 and the positive rate of the two groups were compared and analyzed Changes of serum CA19-9 level in patients with different stages of pancreatic cancer. Results The levels of serum CA19-9 and the positive rate of CA19-9 in the observation group were higher than those in the control group (P <0.05). With the increase of the staging of pancreatic cancer, the level of CA19-9 increased, but there was no significant difference in CA19-9 between different stages Significance (P> 0.05). Conclusion CA19-9 can be used as an indicator of early pancreatic cancer diagnosis and staging.